| scholarly article | Q13442814 |
| P50 | author | Patrick Provost | Q37392016 |
| Claudius U Meyer | Q40366544 | ||
| Abdimajid Osman | Q57902212 | ||
| P2093 | author name string | Walter E Hitzler | |
| Peter Hellstern | |||
| Eric Boilard | |||
| Patricia Landry | |||
| Benoit Laffont | |||
| Eleftherios C Vamvakas | |||
| Aurélie Corduan | |||
| P2860 | cites work | Platelet microRNAs: From platelet biology to possible disease biomarkers and therapeutic targets. | Q38044999 |
| Platelet mitochondrial function: from regulation of thrombosis to biomarker of disease | Q38077217 | ||
| Detection of human Dicer and Argonaute 2 catalytic activity | Q39551319 | ||
| Accurate RT-qPCR gene expression analysis on cell culture lysates | Q40367985 | ||
| Platelet size: measurement, physiology and vascular disease | Q41059731 | ||
| The combined effect of platelet storage media and intercept pathogen reduction technology on platelet activation/activability and cellular apoptosis/necrosis: Lisbon-RBS experience | Q42492801 | ||
| Functional characteristics of buffy-coat PLTs photochemically treated with amotosalen-HCl for pathogen inactivation | Q44783536 | ||
| Activated platelets can deliver mRNA regulatory Ago2•microRNA complexes to endothelial cells via microparticles | Q44791838 | ||
| Parallel comparison of apheresis-collected platelet concentrates stored in four different additive solutions | Q45030789 | ||
| Polymerase chain reaction inhibition assay documenting the amotosalen-based photochemical pathogen inactivation process of platelet concentrates | Q45303414 | ||
| Meta‐analysis of the randomized controlled trials of the hemostatic efficacy and capacity of pathogen‐reduced platelets | Q46115563 | ||
| Evaluation of platelet mitochondria integrity after treatment with Mirasol pathogen reduction technology. | Q46526695 | ||
| Effect of the psoralen-based photochemical pathogen inactivation on mitochondrial DNA in platelets | Q46803549 | ||
| Platelet ADP response deteriorates in synthetic storage media | Q46915204 | ||
| In vitro assessment of buffy-coat derived platelet components suspended in SSP+ treated with the INTERCEPT Blood system | Q47574266 | ||
| Platelet derived cytokine accumulation in platelet concentrates treated for pathogen reduction. | Q50521947 | ||
| Aberrant expression of microRNA in polycythemia vera. | Q53474698 | ||
| In vitro evaluation of metabolic changes and residual platelet responsiveness in photochemical treated and gamma-irradiated single-donor platelet concentrates during long-term storage. | Q53563734 | ||
| Annotation of mammalian primary microRNAs | Q57008990 | ||
| Studies on human platelets. I. Synthesis of platelet protein in a cell-free system | Q72221450 | ||
| Alteration of the platelet transcriptome in chronic kidney disease | Q84630706 | ||
| Platelet microRNA profiles and the effect of pathogen reduction on platelet function | Q84880311 | ||
| Functional characteristics of S-59 photochemically treated platelet concentrates derived from buffy coats | Q95719295 | ||
| Pathogen-reduced platelets for the prevention of bleeding | Q24199041 | ||
| VAMP8/endobrevin is overexpressed in hyperreactive human platelets: suggested role for platelet microRNA | Q24609475 | ||
| MicroRNAs: target recognition and regulatory functions | Q24609584 | ||
| MicroRNAs in platelet production and activation | Q24622537 | ||
| Platelets amplify inflammation in arthritis via collagen-dependent microparticle production | Q24627618 | ||
| Signal-dependent translation of a regulatory protein, Bcl-3, in activated human platelets | Q24675173 | ||
| Statistical analysis of real-time PCR data | Q25255616 | ||
| Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method | Q25938999 | ||
| De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin | Q28195114 | ||
| Platelet microRNA-mRNA coexpression profiles correlate with platelet reactivity. | Q30500885 | ||
| Whole blood microvolume laser scanning cytometry for monitoring resting and activated platelets | Q30697536 | ||
| Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial | Q33345486 | ||
| Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial | Q33360736 | ||
| Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial | Q33369694 | ||
| Programmed anuclear cell death delimits platelet life span. | Q33374664 | ||
| A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology | Q33389725 | ||
| Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction | Q33389833 | ||
| BCL2/BCL-X(L) inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation | Q33395270 | ||
| Meta-analysis of the studies of bleeding complications of platelets pathogen-reduced with the Intercept system | Q33397396 | ||
| Implementation of the INTERCEPT Blood System for Platelets into routine blood bank manufacturing procedures: evaluation of apheresis platelets. | Q33448189 | ||
| Biosynthesis of major platelet proteins in human blood platelets. | Q33457156 | ||
| Rough Endoplasmic Reticulum and Ribosomes in Blood Platelets | Q33468695 | ||
| Existence of a microRNA pathway in anucleate platelets | Q34025954 | ||
| Characterization of human platelet microRNA by quantitative PCR coupled with an annotation network for predicted target genes | Q34173401 | ||
| Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates | Q34423678 | ||
| Fundamentals of the psoralen-based Helinx technology for inactivation of infectious pathogens and leukocytes in platelets and plasma | Q34451435 | ||
| The repertoire and features of human platelet microRNAs | Q34506593 | ||
| The sequence structures of human microRNA molecules and their implications | Q34562765 | ||
| Mitochondria regulate platelet metamorphosis induced by opsonized zymosan A--activation and long-term commitment to cell death | Q34921671 | ||
| Circulating human blood platelets retain appreciable amounts of poly (A)+ RNA. | Q35139827 | ||
| Genome-wide RNA-seq analysis of human and mouse platelet transcriptomes. | Q35346534 | ||
| Platelets and platelet-like particles mediate intercellular RNA transfer | Q36058568 | ||
| Pathogen inactivation: making decisions about new technologies. Report of a consensus conference | Q37013124 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | microRNA | Q310899 |
| P304 | page(s) | 154-163 | |
| P577 | publication date | 2014-04-21 | |
| P1433 | published in | Platelets | Q1573582 |
| P1476 | title | Effects of pathogen reduction systems on platelet microRNAs, mRNAs, activation, and function | |
| P478 | volume | 26 |
| Q52778575 | 2016 proceedings of the National Heart, Lung, and Blood Institute's scientific priorities in pediatric transfusion medicine. |
| Q38822804 | Aging of platelets stored for transfusion |
| Q42368316 | Amotosalen/ultraviolet A pathogen inactivation technology reduces platelet activatability, induces apoptosis and accelerates clearance |
| Q44102123 | Blood-Borne Pathogens: A Canadian Blood Services Centre for Innovation Symposium. |
| Q91296157 | Cold-stored platelets: A product with function optimized for hemorrhage control |
| Q50215380 | Comparison of the Hemostatic Efficacy of Pathogen-Reduced Platelets vs Untreated Platelets in Patients With Thrombocytopenia and Malignant Hematologic Diseases: A Randomized Clinical Trial |
| Q51413251 | Composition of growth factors and cytokines in lysates obtained from fresh versus stored pathogen-inactivated platelet units. |
| Q54200365 | Development of a mitochondrial DNA real-time polymerase chain reaction assay for quality control of pathogen reduction with riboflavin and ultraviolet light. |
| Q28546504 | Differential Expression Analysis by RNA-Seq Reveals Perturbations in the Platelet mRNA Transcriptome Triggered by Pathogen Reduction Systems |
| Q54430124 | Evaluation of positive and false-positive results in syphilis screening of blood donors in Rio de Janeiro, Brazil. |
| Q37417319 | Expression and function of purinergic receptors in platelets from apheresis-derived platelet concentrates |
| Q53251240 | Functional characteristics and clinical effectiveness of platelet concentrates treated with riboflavin and ultraviolet light in plasma and in platelet additive solution. |
| Q90749251 | MicroRNAs as a Potential Quality Measurement Tool of Platelet Concentrate Stored in Blood Banks-A Review |
| Q50228060 | Microparticle and mitochondrial release during extended storage of different types of platelet concentrates |
| Q33441980 | Pathogen reduction technologies: The pros and cons for platelet transfusion |
| Q89184302 | Pathogen-Inaktivierungssysteme für Thrombozytenkonzentrate : Stellungnahme |
| Q38812483 | Peculiarities of studying the effects of pathogen reduction technologies on platelets |
| Q91971794 | Platelet Inflammatory Response to Stress |
| Q38581119 | Platelet MicroRNAs: An Overview |
| Q91714481 | Platelet Pathogen Reduction Technologies Alter the MicroRNA Profile of Platelet-Derived Microparticles |
| Q92390852 | Proceedings of the Food and Drug Administration public workshop on pathogen reduction technologies for blood safety 2018 (Commentary, p. 3026) |
| Q51626212 | Riboflavin and ultraviolet illumination affects selected platelet mRNA transcript amounts differently. |
| Q33457486 | The miRNA Profile of Platelets Stored in a Blood Bank and Its Relation to Cellular Damage from Storage. |
| Q40273685 | The platelets' perspective to pathogen reduction technologies |
| Q38999088 | The role of microRNAs in platelet biology during storage |
| Q36414235 | The storage lesions: From past to future. |
| Q54977038 | Ultraviolet-Based Pathogen Inactivation Systems: Untangling the Molecular Targets Activated in Platelets. |
| Q50591463 | miR-570 interacts with mitochondrial ATPase subunit g (ATP5L) encoding mRNA in stored platelets. |
Search more.